Many consumer groups are concerned that for FDA and the public to be confident in the objectivity of the advice FDA receives, every effort must be made to minimize the number of conflicted experts that serve on these committees.

H.R. 3202, the Novel Device Regulatory Relief Act, appears to be intended to streamline the de novo process for FDA approval of medical devices.

I mean, I as a politician get that from both ends, you know, 'Why aren't you moving quickly?' On the other hand, everything has to be safe.

We are going to move forward with them.

Thank you. Now, would it be helpful to have additional resources to conduct more foreign inspections of brand facilities?

I appreciate the industry's ability to work with the FDA and move forward on a strong agreement.

Clearly, bringing generic drugs to market faster should be a priority.

I am encouraged by the bipartisan nature of these efforts, and I look forward to working with my colleagues.

As you know, Mr. Dingell, Ms. DeGette, myself, and Mr. Waxman have introduced the Drug Safety Enhancement Act that gives the FDA authorities and resource to address the problem of these ingredients and drugs from overseas.

the imbalance of inspection requirements between U.S. and foreign manufacturing facilities creates an uneven playing field for pharmaceutical plants in the U.S.

Both you and the FDA Commissioner Hamburg gave assurances to the generic industry that the Biosimilar User Fee Program would receive 20 million in funding.

Are there any new authorities that would help the FDA in making sure that companies meet those responsibilities?